Comparison of pharmacokinetics, efficacy and toxicity profile of gemcitabine using two different administration regimens in Chinese patients with non-small-cell lung cancer
- 1 April 2007
- journal article
- research article
- Published by Zhejiang University Press in Journal of Zhejiang University-SCIENCE B
- Vol. 8 (5) , 307-313
Abstract
To conduct a randomized comparative trial of pharmacokinetics, efficacy and toxicity profile treatment with 1200 mg/m2 gemcitabine using standard 30-min infusion or fixed dose rate (FDR) infusion [10 mg/(m2·min)] on days 1 and 8 plus carboplatin AUC (area under curve) 5 on day 1 in Chinese non-small-cell cancer patients. Twelve patients were enrolled in this study. Plasma gemcitabine concentrations were measured by ion-pair reversed phase high performance liquid chromatography. Antitumoral activity and toxicity of gemcitabine was assessed according to World Health Organization criteria. The obtained mean parameters, such as T 1/2 (elimination half time), AUC, and CL (clearance), were consistent with those reported in literature. Qualified response rate in our study was 33.3% for standard arm and 50% for FDR arm. Additional 50% and 33.3% patients contracted stable disease (SD) in standard arm and FDR arm, respectively. The predominant toxicity was hematologic, and patients in the standard infusion arm experienced consistently more hematologic toxicity. Pharmacokinetic and clinical data in this trial support the continued evaluation of the FDR infusion strategy with gemcitabine.Keywords
This publication has 17 references indexed in Scilit:
- Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic AdenocarcinomaJournal of Clinical Oncology, 2003
- Gemcitabine pharmacokinetics and interaction with paclitaxel in patients with advanced non-small-cell lung cancerCancer Chemotherapy and Pharmacology, 2003
- Gemcitabine/carboplatin in advanced non-small cell lung cancerLung Cancer, 2002
- Gemcitabine versus gemcitabine/carboplatin in advanced non–small cell lung cancer: Preliminary findings in a phase III trial of the Swedish Lung Cancer Study GroupSeminars in Oncology, 2002
- Phase I and pharmacokinetic study of two sequences of gemcitabine and docetaxel administered weekly to patients with advanced cancerCancer Chemotherapy and Pharmacology, 2001
- Front line chemotherapy with four different schedules of gemcitabine and carboplatin in stage IV non-small cell lung cancer (NSCLC)European Journal of Cancer, 2001
- Carboplatin (C) and Gemcitabine (G) in advanced non small cell lung cancer (NSCLC): An effective and well tolerated regimenLung Cancer, 2000
- Gemcitabine and Paclitaxel: Pharmacokinetic and Pharmacodynamic Interactions in Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 1999
- Clinical, toxicological and pharmacological aspects of gemcitabineCancer Treatment Reviews, 1996
- Reporting results of cancer treatmentCancer, 1981